Efficacy of esophagoprotection with short periods of withdrawal of maintenance therapy with proton pump inhibitors in patients with Barrett's esophagus
- Authors: Kucheryavyy Y.A.1, Movtaeva P.R.2, Zayratyants O.V.2, Andreev D.N.2, Shaburov R.I.2, Barkalova E.V.2, Maev I.V.2
-
Affiliations:
- Ilyinskaya Hospital
- Yevdokimov Moscow State University of Medicine and Dentistry
- Issue: Vol 23, No 5 (2021)
- Pages: 417-421
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/95478
- DOI: https://doi.org/10.26442/20751753.2021.5.200895
- ID: 95478
Cite item
Full Text
Abstract
Aim. Evaluation of the effectiveness of esophagoprotection in covering up short periods of withdrawal of maintenance therapy with proton pump inhibitors (PPIs) in patients with Barrett's esophagus (BE). Materials and methods. A retrospective analysis of the data of patients with histologically verified BE who received outpatient PPI therapy for at least 12 months was carried out. This cohort was divided into two groups to compare depending on the treatment regimen received. The first group included only patients who take PPIs constantly, while the second group included patients who had periodic interruptions in taking PPIs. In the second group, we analyzed only cases where to cover up the periods of PPI withdrawal the patients used the esophagoprotector Alfasoxx (10 ml 4 times a day, after each meal and at night). In the cohort, demographic data (age, gender), risk factors, length of the BE segment, degree of dysplasia, number of relapses of erosive esophagitis, and the data of high-resolution manometry on movement disorders of the thoracic esophagus (ineffective motility and lack of contractility) were analyzed. Results. The study included 39 patients (28 men and 11 women) with histologically verified BE. The average age was 57,1538 years (95% confidence interval 53.4269-60.8808). The gender structure was dominated by men (n=28). The duration of BE history in the analyzed cohort was 5.6769 years (95% confidence interval, 4.6161-6.7378). The first group consisted of 23 patients who take PPIs constantly. The second group consisted of 16 patients who had periodic interruptions in taking PPIs, which were covered by the esophagoprotector Alfasoxx. In the analyzed cohort, there were no significant differences between the groups in the average length of the BE segment, the number of patients with a long BE segment, the degree of dysplasia, the number of relapses of erosive esophagitis, and the rate of movement disorders of the thoracic esophagus. Conclusion. In routine practice, there are reasons for the temporary withdrawal of PPIs in patients with BE, which requires the administration of course esophagoprotection to cover up the risks. The results of this retrospective comparative study demonstrate the effectiveness of this strategy.
Full Text
##article.viewOnOriginalSite##About the authors
Yury A. Kucheryavyy
Ilyinskaya Hospitalканд. мед. наук, доц., зав. Glukhovo, Moscow Region, Russia
Petimat R. Movtaeva
Yevdokimov Moscow State University of Medicine and Dentistryсоискатель каф. Moscow, Russia
Oleg V. Zayratyants
Yevdokimov Moscow State University of Medicine and Dentistryд-р мед. наук, проф., зав. каф. Moscow, Russia
Dmitrii N. Andreev
Yevdokimov Moscow State University of Medicine and Dentistry
Email: dna-mit8@mail.ru
канд. мед. наук, доц. каф. Moscow, Russia
Rafik I. Shaburov
Yevdokimov Moscow State University of Medicine and Dentistryканд. мед. наук, ассистент каф. Moscow, Russia
Elena V. Barkalova
Yevdokimov Moscow State University of Medicine and Dentistryассистент каф. Moscow, Russia
Igor V. Maev
Yevdokimov Moscow State University of Medicine and Dentistryакад. РАН, д-р мед. наук, проф., зав. каф. Moscow, Russia
References
- Зайратьянц О.В., Маев И.В., Смольянникова В.А., Мовтаева П.Р Патологическая анатомия пищевода Баррета. Архив патологии. 2011;73(3):21-6
- Tantau M, Laszlo M, Tantau A. Barrett's Esophagus - State of the Art. Chirurgia (Bucur). 2018;113(1):46-60. doi: 10.21614/chirurgia.113.1.46
- Ивашкин В.Т., Маев И.В., Трухманов А.С., и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70-97
- Маев И.В., Бусарова Г.А., Андреев Д.Н. Болезни пищевода. М.: ГЭОТАР-Медиа, 2019.
- Taylor JB, Rubenstein JH. Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett's esophagus. Am J Gastroenterol. 2010;105(8):1729,1730-7;quiz 1738. doi: 10.1038/ajg.2010.194
- Eusebi LH, Cirota GG, Za gari RM, Ford AC. Global prevalence of Barrett's oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and metaanalysis. Gut. 2021;70(3):456-63. doi: 10.1136/gutjnl-2020-321365
- Mohy-Ud-Din N, Krill TS, Shah AR, et al. Barrett's esophagus: What do we need to know? Dis Mon. 2019 Feb 23. doi: 10.1016/j.disamonth.2019.02.003
- ASGE standards of practice committee, Qumseya B, Sultan S, Bain P, et al; ASGE Standards of Practice Committee Chair. ASGE guideline on screening and surveillance of Barrett's esophagus. Gastrointest Endosc. 2019;90(3):335-59.e2. doi: 10.1016/j.gie.2019.05.012
- Qumseya BJ, Bukannan A, Gendy S, et al. Systematic review and meta-analysis of prevalence and risk factors for Barrett's esophagus. Gastrointest Endosc. 2019;90(5):707-717.e1. doi: 10.1016/j.gie.2019.05.030
- Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Ожирение и коморбидность. М., 2016
- Маев И.В., Андреев Д.Н., Кучерявый Ю.А., Щегланова М.П. Аденокарцинома пищевода: факторы риска и современные стратегии скрининга. Рос. журн. гастроэнтерологии, гепатологии, колопрок-тологии. 2017;27(2):4-12
- Krishnamoorthi R, Mohan BP, Jayaraj M, et al. Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis. Gastrointest Endosc. 2020;91(1):3-10.e3. doi: 10.1016/j.gie.2019.07.037
- Krishnamoorthi R, Singh S, Ragunathan K, et al. Factors Associated With Progression of Barrett's Esophagus: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16(7):1046-1055.e8. doi: 10.1016/j.cgh.2017.11.044
- Fitzgerald RC, di Pietro M, Ragunath K, et al; British Society of Gastroenterology. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014;63(1):7-42. doi: 10.1136/gutjnl-2013-305372
- Shaheen NJ, Falk GW, Iyer PG, Gerson LB; American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol. 2016;111(1):30-50; quiz 51. doi: 10.1038/ajg.2015.322
- Chen Y, Sun C, Wu Y, et al. Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis. J Cancer Res Clin Oncol. 2021 Feb 11. doi: 10.1007/s00432-021-03544-3
- Кучерявый Ю.А., Мовтаева П.Р., Андреев Д.Н., и др. Снижение риска рецидива симптоматики при применении эзофагопротектора у пациентов, требующих временную отмену анти-секреторной терапии. Эффективная фармакотерапия. 2021
- Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483-90. doi: 10.1016/j.cgh.2012.12.011
- Su T, Lai S, Lee A, et al. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol. 2018;53(1):27-36. doi: 10.1007/s00535-017-1371-9
- Schmulson MJ, Frati-Munari AC. Bowel symptoms in patients that receive proton pump inhibitors. Results of a multicenter survey in Mexico. Rev Gastroenterol Mex. 2019;84(1):44-51. doi: 10.1016/j.rgmx.2018.02.008
- Losurdo G, Salvatore D'Abramo F, Indellicati G, et al. The Influence of Small Intestinal Bacterial Overgrowth in Digestive and Extra-Intestinal Disorders. Int J Mol Sci. 2020;21(10):3531. doi: 10.3390/ijms21103531
- Shah A, Talley NJ, Jones M, et al. Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. Am J Gastroenterol. 2020;115(2):190-201. doi: 10.14309/ajg.0000000000000504
- Chen B, Kim JJ, Zhang Y, et al. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol. 2018;53(7):807-18. doi: 10.1007/s00535-018-1476-9
- Тактика врача-гастроэнтеролога. Практическое руководство. Под ред. И.В. Маева. М., 2021
- Маев И.В., Самсонов А.А., Андреев Д.Н. Роль и место антацидов в современных алгоритмах терапии кислотозависимых заболеваний. Фарматека. 2013;2(255):65-72
- Маев И.В., Гуленченко Ю.С., Андреев Д.Н., и др. Дуоденогастроэзофагеальный рефлюкс: клиническое значение и подходы к терапии. Consilium Medicum. 2014;16(8):5-8
- Маев И.В., Андреев Д.Н., Кучерявый Ю.А., Шабуров Р.И. Современные достижения в лечении гастроэзофагеальной рефлюксной болезни: фокус на эзофагопротекцию. Терапевтический архив. 2019;91(8):4-11
- Эмбутниекс Ю.В., Валитова Э.Р., Бордин Д.С. Новый подход к лечению гастроэзофагеальной рефлюксной болезни: защита слизистой оболочки пищевода. Эффективная фармакотерапия. 2019;15(18):16-22
- Palmieri B, Corbascio D, Capone S, Lodi D. Preliminary clinical experience with a new natural compound in the treatment of esophagitis and gastritis: symptomatic effect. Trends Med. 2009;9:219-25.
- Palmieri B, Merighi A, Corbascio D, et al. Fixed combination of hyaluronic acid and chondroitinsulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastroesophageal reflux. Eur Rev Med Pharmacol Sci. 2013;17:3272-8.
- Savarino V, Pace F, Scarpignato C. Esoxx Study Group Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease - efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. Aliment Pharmacol Ther. 2017;45:631-42.
Supplementary files
